Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AJN 003
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : $5.0 million
Deal Type : Series A Financing
AltrixBio Raises $5 Million Series A Financing to Advance Lead Candidate into the Clinic
Details : The funding will accelerate the clinical entry of AJN 003, a first-in-class oral therapy designed to transform the treatment of type 2 diabetes and metabolic diseases.
Product Name : AJN 003
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 16, 2025
Lead Product(s) : AJN 003
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : $5.0 million
Deal Type : Series A Financing